Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000798458 | SCV000938075 | benign | Tuberous sclerosis 2 | 2023-12-11 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001759515 | SCV001997513 | uncertain significance | not provided | 2019-12-31 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Has not been previously published as pathogenic or benign to our knowledge |
Genome- |
RCV000798458 | SCV002040711 | uncertain significance | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002458444 | SCV002739386 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-02-26 | criteria provided, single submitter | clinical testing | The p.Q864H variant (also known as c.2592G>C), located in coding exon 22 of the TSC2 gene, results from a G to C substitution at nucleotide position 2592. The glutamine at codon 864 is replaced by histidine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |